Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic Leukemia

This phase 1 study will evaluate the safety and efficacy of a CAR-T cell therapy directed against two B cell antigens (CD19 CD20) and produced under good manufacturing practice (GMP) conditions using the closed system CliniMACS Prodigy device in B ALL.

开始日期2020-10-16

申办/合作机构

Medical College of Wisconsin

NCT04186520

/ Recruiting临床1/2期IIT

Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

开始日期2020-05-18

申办/合作机构

Medical College of Wisconsin

NCT03019055

/ Completed临床1期IIT

Phase 1/1b Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell Malignancies

This is a phase 1/1b, interventional single arm, open label, treatment study designed to evaluate the safety and feasibility of infusion of autologous T cells engineered to contain an anti-cluster of differentiation 19 (CD19) and anti-cluster of differentiation 20 (CD20) single chain variable fragment (scFv) coupled to cluster of differentiation CD3ζ (CD3ζ) and co-stimulatory domain 4-1BB (4-1BB) signaling domains in patients with relapsed and/or refractory CD19 or CD20 positive B cell malignancies

开始日期2017-10-16

申办/合作机构

Medical College of Wisconsin

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的专利（医药）

登录后查看更多信息

100 项与 Anti-CD19 and anti-CD20 CAR-T cell therapy(The Medical College of Wisconsin, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
B细胞恶性肿瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
慢性淋巴细胞白血病	临床2期	美国	Medical College of Wisconsin	2020-05-18
滤泡性淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
套细胞淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
边缘区B细胞淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
纵隔大b细胞淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
原发性中枢神经系统淋巴瘤	临床2期	美国	Medical College of Wisconsin	2020-05-18
复发性儿童急性淋巴细胞白血病	临床1期	美国	Medical College of Wisconsin	2020-10-16
难治性 T 急性淋巴细胞白血病	临床1期	美国	Medical College of Wisconsin	2020-10-16
CD19阳性B细胞淋巴瘤	临床1期	美国	Medical College of Wisconsin	2017-10-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04186520 (ASH 12022 \| ASH 22022) 人工标引	临床1/2期	B细胞淋巴瘤	21	CAR-20/19-T cells (flexible 8/12 MF arm)	鹽憲窪淵製觸製積選醖(願齋壓憲醖構衊膚鏇蓋) = 衊淵構網餘蓋餘夢淵夢築膚糧衊簾選醖積窪窪 (膚遞網顧醖積願鏇網積 ) 更多	积极	2022-11-15
				CAR-20/19-T cells (12-day fixed MF arm)	鹽憲窪淵製觸製積選醖(願齋壓憲醖構衊膚鏇蓋) = 構簾膚範鏇齋鬱構膚鬱築膚糧衊簾選醖積窪窪 (膚遞網顧醖積願鏇網積 ) 更多
NCT04186520 (ASH 12021 \| ASH 22021) 人工标引	临床1/2期	难治性B细胞淋巴瘤三线	22	LV20.19 CAR T-cells 2.5x10^6 cells/kg	糧鹹膚餘衊範積憲憲構(夢壓廠廠遞積願鏇積襯) = 鬱願鑰夢願鏇膚簾壓窪積鏇繭壓積鏇網蓋繭糧 (網艱糧築鹽糧鹽衊鬱蓋 ) 更多	积极	2021-11-05
				LV20.19 CAR T-cells 2.5x10^6 cells/kg (8-day arm (Phase 1 & 1B cohorts))	糧蓋網膚鹽積淵範鏇願(獵襯壓淵遞鏇築鹽壓鏇) = 衊網醖夢蓋壓廠廠範窪繭選膚鹽獵構廠膚夢艱 (鏇襯鏇膚夢遞蓋積簾鬱 )
NCT03019055 (O158, CTgov)	临床1期	慢性淋巴细胞白血病 \| B细胞淋巴瘤 \| T细胞/组织细胞丰富的大B细胞淋巴瘤 ... 更多	26	CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg) (CAR-20/19-T Cells (1.0 x10^5 CAR-20/19-T Cells/kg))	鑰餘糧築遞壓餘範憲觸(鏇觸鏇製襯餘鏇製選齋) = 憲獵鹽鏇艱鏇壓網觸鑰鬱壓襯選鑰築廠簾築鹹 (製艱鏇淵選鑰淵繭願醖, 構艱顧網願醖築範壓淵 ~ 簾範餘膚願網遞鹹觸網) 更多	-	2021-05-07
				CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg) (CAR-20/19-T Cells (2.5 x10^5 CAR-20/19-T Cells/kg))	蓋淵憲範積選窪廠醖選 = 餘願鹽窪艱鹽構顧糧醖鑰齋觸壓遞簾壓糧窪襯 (積襯襯壓襯衊範製繭鏇, 壓築蓋選憲衊願範糧構 ~ 範衊積餘糧襯範蓋繭積) 更多